Mazowiecki Szpital Wojewodzki Im. Sw. Jana Pawła II W Siedlcach Sp. z o.o.

The Mazowiecki Szpital Wojewodzki Im. Sw. Jana Pawła II in Siedlce is actively investigating female urogenital diseases and related cancers. Current trials focus on advanced endometrial cancer, high‑grade serous ovarian cancer, and intermediate‑risk cervical cancer, aiming to improve adjuvant therapy, evaluate novel immunotherapy combinations, and test targeted maintenance strategies.

• Immunotherapy plus chemotherapy in high‑grade serous ovarian cancer
• Adjuvant pembrolizumab versus standard care in endometrial carcinoma
• Maintenance therapy with antibody‑drug conjugates after platinum response
• Neoadjuvant checkpoint inhibitor trials in cervical cancer

With 51 active studies and a team of nine investigators, the site contributes to the development of personalized treatments for women’s cancers across Poland.

Trials at the centre also address neoplasms of the respiratory tract, particularly non‑small cell lung cancer (NSCLC) and extensive‑stage small cell lung cancer. Objectives include testing new checkpoint inhibitor combos, assessing maintenance regimens after chemoradiation, and comparing oral versus intravenous immunotherapies.

• Durvalumab plus oleclumab after concurrent chemoradiation for unresectable Stage III NSCLC
• Oral pembrolizumab formulation versus IV infusion in Stage IV NSCLC
• Combination of TLR7/8 agonist with pembrolizumab in locally advanced disease
• Novel ADC versus standard chemotherapy in extensive‑stage SCLC

The department’s thoracic oncology program leverages advanced imaging and biomarker analysis to accelerate the evaluation of innovative lung‑cancer therapies.

The site’s portfolio includes studies on melanoma and other cutaneous malignancies, evaluating next‑generation antibody‑drug conjugates and combination immunotherapies to enhance response rates in advanced disease.

• Phase 3 comparison of a new ADC versus standard care in advanced melanoma
• Combination of ficerafusp alfa with pembrolizumab for melanoma
• Subcutaneous pembrolizumab with hyaluronidase versus IV administration in metastatic melanoma
• Safety run‑in of T‑cell engager therapies in melanoma patients

By integrating translational research with clinical evaluation, the centre aims to bring more effective skin‑cancer treatments to patients sooner.

Research on renal cell carcinoma and advanced prostate cancer is also prominent, with trials investigating hypoxia‑targeted agents, dual checkpoint blockade, and novel hormone‑resistance strategies.

• Belzutifan plus pembrolizumab versus placebo in RCC
• MK‑5684 versus enzalutamide in metastatic castration‑resistant prostate cancer
• Belzutifan and zanzalintinib versus cabozantinib in advanced kidney cancer
• I‑DXd versus docetaxel in metastatic castration‑resistant prostate cancer

The department’s multidisciplinary team supports these studies with state‑of‑the‑art imaging and molecular profiling, fostering progress in hard‑to‑treat urologic cancers.